The Cancer and Leukemia Group B (CALGB) Statistical Center has primary responsibility for all statistical, data management, computing, information systems, and related activities for the CALGB. Faculty and staff statisticians and data coordinators collaborate closely with study chairs, committee chairs, and other investigators on the design, conduct, analysis, and reporting of all clinical trials and other studies conducted by the CALGB. The Statistical Center has responsibility for central data quality control and database administration. All clinical data are sent to the Statistical Center for editing, verification, and entry into the official CALGB database. Scientific laboratory data are transmitted electronically and become part of the official record. Statisticians and datacoordinators from the Statistical Center are assigned to each CALGB study. They work closely with study chairs to monitor the studies and to prepare all necessary reports, analyses, and manuscripts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA033601-35
Application #
8467680
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2014-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
35
Fiscal Year
2013
Total Cost
$4,309,956
Indirect Cost
$1,045,361
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2014) A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemp Clin Trials 38:198-203
Eisfeld, Ann-Kathrin; Schwind, Sebastian; Patel, Ravi et al. (2014) Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal 7:ra36
Becker, H; Maharry, K; Mrózek, K et al. (2014) Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia 28:1754-8
Halabi, Susan; Rini, Brian; Escudier, Bernard et al. (2014) Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 120:52-60
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Boughey, Judy C; McCall, Linda M; Ballman, Karla V et al. (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608-14; discussion 614-6

Showing the most recent 10 out of 318 publications